Skip to search formSkip to main contentSkip to account menu

S16020

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

NSC 659687

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
In vitro cytotoxicity of S16020-2, a new olivacine derivative
SummaryS16020-2 is a new olivacine derivative which has recently shown a marked antitumor activity in various experimental models… 
2003
2003
In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts
New active drugs are needed for the treatment of primary brain tumors in both children and adults. S16020 is a cytotoxic… 
2001
2001
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
The combination of a novel topoisomerase II inhibitor, S16020, and ionizing radiation (IR) was investigated with the aim of… 
1999
1999
Phase I trial and pharmacokinetic (PK) study of S16020 according to a weekly and every 2 week (W) schedule in cancer patients (PT)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)